

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

SPECIAL FEATURES

CCR Translations

- 2545** **CHIP'ing Signal from Noise in Liquid Biopsy**
Elsa Bernard and Jean-Baptiste Micol
See related article, p. 2710
- 2547** **Pretargeting: Bridging the Two Worlds of Radiopharmaceutical Probes**
Yuriko Mori, Jens Cardinale, and Frederik L. Giesel
See related article, p. 2719
- 2550** **Antibody–Drug Conjugates in Non–Small Cell Lung Cancer: Where Are the Target and the Biomarker?**
Fred R. Hirsch
See related article, p. 2767

CCR Perspectives in Regulatory Science and Policy

- 2552** **Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better**
Kristin M. Wessel, Nicole Drezner, Stacy S. Shord, Mirat Shah, Marc R. Theoret, and Martha Donoghue

Reviews

- 2556** **Facts and Hopes in Radioimmunotherapy of Oligometastatic Disease**
Daniel Huang, Connor Lynch, Sean P. Pitroda, and Ralph R. Weichselbaum
- 2565** **Targeting the MAP Kinase Pathway in Colorectal Cancer: A Journey in Personalized Medicine**
Jordan W. Appleyard, Christopher J.M. Williams, Paolo Manca, Filippo Pietrantonio, and Jenny F. Seligmann

Perspectives

- 2573** **Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials**
Kai Chen, Ting-Yu Chen, Yiming Zhang, Ruitao Lin, and Ying Yuan
- 2581** **Pediatric Cancer Predisposition and Surveillance Update: Summary Perspective and Future Directions**
Garrett M. Brodeur, Lisa R. Diller, Kim E. Nichols, Sharon E. Plon, Christopher C. Porter, and David Malkin

CLINICAL TRIALS: TARGETED THERAPY

- 2589** **Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial**
Dechuang Jiao, Jianghua Qiao, Xianfu Sun, Chengzheng Wang, Zhenduo Lu, Chongjian Zhang, Lianfang Li, Min Yan, Yueqing Feng, Yong Zhou, Miao Deng, Xinlan Liu, Mingde Ma, Haiquan Jia, Qingxin Xia, Geok Hoon Lim, Naohiro Ishii, Armando Orlandi, Fernando Hernanz, Xiuchun Chen, and Zhenzhen Liu
- 2599** **Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study**
Lara E. Davis, Limin Zhu, Emile Latour, Nathan McMahon, Go Nishikawa, Florence Choo, Kevin D. Nusser, Janét Pittsenbarger, Reid Burch, Byung Park, Gordon B. Mills, Jessica L. Davis, Monika Davare, and Christopher W. Ryan
- 2608** **Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia**
Shiyuan Wang, Mingyan Jiang, Yaqin Wang, Lixian Chang, Beibei Zhao, Xiaoming Liu, Benquan Qi, Shuchun Wang, Tianfeng Liu, Xiaoyan Zhang, Yumei Chen, Fang Liu, Ye Guo, Xiaojuan Chen, Li Zhang, Yao Zou, Wenyu Yang, Ju Gao, Xiaofan Zhu, and Min Ruan

CLINICAL TRIALS: IMMUNOTHERAPY

- 2617** **INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma**
Jérôme Fayette, Lisa Licitra, Kevin Harrington, Robert Haddad, Lillian L. Siu, Yi-Chun Liu, Makoto Tahara, Jean-Pascal Machiels, Danny Rischin, Tanguy Y. Seiwert, Robert L. Ferris, Ulrich Keilholz, Amanda Psyrrri, Bhumsuk Keam, Paolo Bossi, Robert Metcalf, Ching-Yun Hsieh, Paul M.J. Clement, Pavel Isaev, Ali Mudunov, José Dinis, Ann Hoebe, Stefan Kasper, Konrad Klinghammer, Michael Hwang, Jorge Blando, Olivier Serrano, Dario Ruscica, Roger B. Cohen; for the INTERLINK-1 investigators

TABLE OF CONTENTS

2628 **Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFN α**

Els M.E. Verdegaa, Anique L.C. Verpoorte, Monique K. van der Kooij, Linda de Bruin, Marten Visser, Caroline E. van der Minne, Vera Weeda, Inge C.F.M. Roozen, Mare A. Jonker, Inge M. Westra, Pauline Meij, Frank M. Speetjens, Stephanie M. Zunder, Gerrit-Jan Liefers, Saskia J. Santegeets, Sjoerd H. van der Burg, and Ellen H.W. Kapiteijn

2639 **Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma**

Hee-Jin Jang, Meera Patel, Daniel Y. Wang, Sung Wook Kang, Jong Min Choi, Claire Lee, Monica Vilchis, Ji Seon Shim, Sonali Mitra, Priyanka Ranchod, Allen Kuncheria, William Hudson, Peter Jindra, Veronica Lenge De Rosen, Maheshwari Ramineni, Ernest Ramsay Camp, Farrah Kheradmand, R. Taylor Ripley, Shawn S. Groth, Hyun-Sung Lee, and Bryan M. Burt

2655 **A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study**

Amy S. Clark, Fengmin Zhao, Paula Klein, Alberto J. Montero, Carla Falkson, Elisa Krill-Jackson, Kendrith Rowland, Sagar Sardesai, Jason Incorvati, Patrick Dillon, Antonio C. Wolff, Richard Trauger, Thomas C. Heineman, Matthew C. Coffey, and Kathy D. Miller

RESEARCH BRIEFS: PRECISION MEDICINE AND THERAPEUTICS

2663 **Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy**

Mamta Gupta, Hoon Choi, Samantha B. Kemp, Emma E. Furth, Stephen Pickup, Cynthia Clendenin, Margo Orlen, Mark Rosen, Fang Liu, Quy Cao, Ben Z. Stanger, and Rong Zhou

PRECISION MEDICINE AND IMAGING

2675 **Liquid and Tissue Biopsies for Identifying *MET* Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib**

Christian Rolfo, Aurora O'Brate, Christoph Menzel, Rolf Bruns, Dilafruz Juraeva, Christopher Stroh, Andreas John, and Paul K. Paik

2685 **Leveraging Longitudinal Patient-Reported Outcome Trajectories to Predict Survival in Non-Small Cell Lung Cancer**

Jiawei Zhou, Benyam Muluneh, Zhaoyang Wang, Huaxiu Yao, and Jim H. Hughes

2695 **Global Transcriptional Complexity of Estrogen Receptor-Low Positive Breast Cancers in the Prospective Swedish Population-Based SCAN-B Cohort**

Siker Kimbung, Srinivas Veerla, Kadum Muhammad, Anna Ehinger, Johan Vallon-Christersson, Martin Malmberg, and Niklas Loman

2710 **Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer Patients**

Daniel Magee, Valeriy Domenyuk, Jim Abraham, Nieves Perdigones Borderias, Jeff Swensen, Praveena Solipuram, Adanma Ayanambakkam, Raja Mehdi, Jagathi Challagalla, Elisabeth Heath, Megan Landsverk, Magdalena Jurkiewicz, Brian Shimkus, Ian Pinto, Daniel Patterson, David Hsiehchen, Supriya Koya, Bradley Somer, Michel Velez, Anthony F. Shields, Jennifer Cultrera, Jennifer R. Ribeiro, Robert Hahn-Lowry, George W. Sledge, Matthew Oberley, Milan Radovich, and David Spetzler

See related commentary, p. 2545

2719 **Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors**

Edwin C. Pratt, Komal Mandleywala, David Bauer, Alexander Bolaender, Grace Chao, Mark A. Castanares, Emily C. Collins, and Jason S. Lewis

See related commentary, p. 2547

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

2727 **p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer**

Hipacia Werneck Gomes, Natalie L. Lister, Shivakumar Keerthikumar, Birunthi Niranjan, Michelle G. Richards, Andrew Ryan, Edmond M. Kwan, Gail P. Risbridger, and Renea A. Taylor

2741 **Nerve Types and Classification of Neurons Innervating Oral Cancer**

Cindy G. Perez-Pacheco, Laura A. Gonzalez-Maldonado, Allison Furgal, Ligia B. Schmitz, Brian S.C. Constantinescu, Yihan Li, Noam Gannot, Sienna K. Perry, Laura Rozek, Greg Wolf, Joshua J. Emrick, Peng Li, and Nisha J. D'Silva

TABLE OF CONTENTS

- 2756 Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma**
Khushali Jhaveri, Ram Thapa, Dalia Ercan, Aditi Saha, Jerald Noble, Pranit Singh, Johannes Fahrman, Neeraj Saini, Ranran Wu, Jennifer B. Dennison, Sam Hanash, Robert R. Jenq, Karnav Modi, Nicholas Figura, Julio Chavez, Bijal Shah, Taiga Nishihori, Aleksandr Lazaryan, Farhad Khimani, Christina Bachmeier, Kenneth Gage, Asmita Mishra, Fabiana Perna, Marco L. Davila, Jay Spiegel, Kai Rejeski, Marion Subklewe, Frederick L. Locke, Ciara Freeman, Nathan Parker, and Michael D. Jain

- 2767 Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer**
Ioannis P. Trontzas, Mengni He, Anna Wurtz, Charles J. Robbins, Nathaniel Robinson, Katherine Bates, Matthew Liu, Thazin N. Aung, Liam Scott, Nay Chan, Sneha Burela, Jacob Schillo, Daniel C. Liebler, Salisha Hill, Ryan D. Morrison, Ioannis Vathiotis, Konstantinos N. Syrigos, Sarah B. Goldberg, Katerina Politi, and David L. Rimm
See related commentary, p. 2550

- 2777 Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer**
Peter Q. Leung, Eslam A. Elghonaimy, Ahmed M. Elamir, Megan Wachsmann, Song Zhang, Neha Barrows, Hollis Notgrass, Ethan Johnson, Cheryl M. Lewis, Rachel von Ebers, Cassandra Hamilton, Samy Castillo-Flores, Ricardo E. Nunez-Rocha, Grace Josephson, Zhikai Chi, Salwan Al Mutar, Patricio M. Polanco, Nina N. Sanford, Syed M. Ali Kazmi, Matthew R. Porembka, David Hsiehchen, Adam C. Yopp, John C. Mansour, Muhammad S. Beg, Herbert J. Zeh III, and Todd A. Aguilera

- 2793 Antitumor Immunity Mediated by Engineered Stem Cells Exploiting TRAIL-Induced Cell Death and FLT3L Immunomodulation**
Thijs A. van Schaik, Kok-Siong Chen, Nobuhiko Kanaya, Lucia Moreno-Lama, Nicolas W. Freeman, Mian Wang, Wanlu Li, Yu Shrike Zhang, Vladimir Vrbanc, Raymond Huang, Hiroaki Wakimoto, David Reardon, and Khalid Shah

- 2814 Low Allele Frequency Variants Identified on Germline Multi-Gene Panel Testing for Cancer Predisposition Can Suggest the Presence of Constitutional Mosaicism**
Adela Rodriguez-Hernandez, Linda M. Polfus, Brittany L. Bychkovsky, Beth Souders, Aleix Prat, Barbara Adamo, Judy E. Garber, Carolyn Horton, and Huma Q. Rana

- 2824 Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer**
Kalpit Shah, Matthew H. Secrest, Wei Zhou, Shu Wang, Dan Canter, Yuxiang Zhang, Dexter Jin, Ethan Sokol, Malgorzata Nowicka, Armande Ang Houle, Ciara Metcalfe, Steven Gendreau, Carsten Schröder, Matthew Wongchenko, and Gerhard Attard

CORRECTIONS

- 2839 Correction: Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors**
Hyunsoo Kim, Austin A. Whitman, Kamila Wisniewska, Rasha T. Kakati, Susana Garcia-Recio, Benjamin C. Calhoun, Hector L. Franco, Lisa A. Carey, Charles M. Perou, and Philip M. Spanheimer


- 2840 Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity**
Timothy A. Yap, Mike I. Walton, Kyla M. Grimshaw, Robert H. te Poele, Paul D. Eve, Melanie R. Valenti, Alexis K. de Haven Brandon, Vanessa Martins, Anna Zetterlund, Simon P. Heaton, Kathrin Heinzmann, Paul S. Jones, Ruth E. Feltell, Matthias Reule, Steven J. Woodhead, Thomas G. Davies, John F. Lyons, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Neil T. Thompson, and Michelle D. Garrett

TABLE OF CONTENTS

ABOUT THE COVER

The cover shows double immunofluorescence of phosphorylated ERK and CK19 of pancreatic cancer from KPC model. Engagement of KRAS inhibitor to its target was detected by MRI markers and confirmed by reduction of p-ERK immunofluorescence. For details, see the article by Gupta and colleagues on page 2663 of this issue.

doi: 10.1158/1078-0432.CCR-31-13-CVR



NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR's established policies for authors, please go to <https://aacrjournals.org/pages/editorial-policies#coi>.